VisionPoint Advisory Group LLC Has $1.44 Million Position in Amgen Inc. (NASDAQ:AMGN)

VisionPoint Advisory Group LLC increased its position in Amgen Inc. (NASDAQ:AMGN) by 10.8% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 5,558 shares of the medical research company’s stock after acquiring an additional 542 shares during the quarter. VisionPoint Advisory Group LLC’s holdings in Amgen were worth $1,441,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in AMGN. AMF Tjanstepension AB increased its stake in shares of Amgen by 16.9% in the third quarter. AMF Tjanstepension AB now owns 120,389 shares of the medical research company’s stock valued at $38,825,000 after buying an additional 17,387 shares during the period. Swedbank AB boosted its holdings in Amgen by 1.1% in the third quarter. Swedbank AB now owns 538,899 shares of the medical research company’s stock valued at $173,639,000 after acquiring an additional 5,751 shares during the last quarter. Segment Wealth Management LLC boosted its holdings in Amgen by 5.6% in the third quarter. Segment Wealth Management LLC now owns 938 shares of the medical research company’s stock valued at $302,000 after acquiring an additional 50 shares during the last quarter. Elevated Capital Advisors LLC boosted its holdings in Amgen by 2.5% in the third quarter. Elevated Capital Advisors LLC now owns 1,539 shares of the medical research company’s stock valued at $496,000 after acquiring an additional 38 shares during the last quarter. Finally, Lake Street Private Wealth LLC boosted its holdings in Amgen by 10.1% in the third quarter. Lake Street Private Wealth LLC now owns 1,861 shares of the medical research company’s stock valued at $600,000 after acquiring an additional 171 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,589 shares of the firm’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the sale, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at $2,195,228.70. This trade represents a 18.06 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Murdo Gordon sold 8,771 shares of the firm’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $294.79, for a total value of $2,585,603.09. Following the sale, the executive vice president now directly owns 44,186 shares of the company’s stock, valued at approximately $13,025,590.94. This represents a 16.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 35,405 shares of company stock valued at $10,410,596. 0.69% of the stock is owned by insiders.

Analyst Ratings Changes

AMGN has been the topic of several analyst reports. Piper Sandler upped their target price on Amgen from $310.00 to $329.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Truist Financial reduced their target price on Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a report on Wednesday, January 8th. Jefferies Financial Group reiterated a “buy” rating and issued a $380.00 target price on shares of Amgen in a report on Tuesday, November 12th. William Blair restated an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. Finally, Wolfe Research assumed coverage on Amgen in a report on Friday, November 15th. They set a “peer perform” rating on the stock. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Amgen has an average rating of “Hold” and a consensus price target of $314.09.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $297.93 on Friday. The firm has a market capitalization of $160.05 billion, a price-to-earnings ratio of 39.46, a PEG ratio of 2.54 and a beta of 0.56. The stock’s 50 day moving average is $275.62 and its 200-day moving average is $300.75. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Sell-side analysts forecast that Amgen Inc. will post 20.6 EPS for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be given a $2.38 dividend. This is a positive change from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 dividend on an annualized basis and a yield of 3.20%. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s dividend payout ratio is presently 126.09%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.